Principal Human Resources Consultant
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.
I get most excited by disruptive, first-in-class ideas, which is often a messy venture at best. . . and an exciting challenge. I have been fortunate to have opportunities where I could help lead significant change as companies evolved through IPO, M&A, divestitures, periods of high growth (and decline), from R&D to Commercial launch, and net loss up to $1B+ revenue. These companies collectively spanned from 30 to 30,000 employees, including several highlight years ranked among Fortune magazines "100 Best Companies to Work For." Most importantly, I love working with people who love what they do. Life is too short to wish you were somewhere else.
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Jeff York at Seres Therapeutics then you've come to the right place.
Wondering if it's jeff@serestherapeutics.com, jeff.york@serestherapeutics.com, york@serestherapeutics.com, or jyork@serestherapeutics.com? We have the answers for you.